2019
Omics and coagulation disorders in pregnancy
Ornaghi S, Paidas M. Omics and coagulation disorders in pregnancy. 2019, 149-155. DOI: 10.1201/9781315201955-24.Peer-Reviewed Original ResearchFetal growth restrictionOmics technologiesPlacenta-mediated complicationsMaternal thromboembolismSpecific biological sampleCoagulation disordersMolecular basisBiochemical pathwaysRegistry-based studyMessenger RNADifferent clinical conditionsVascular biologyPlacental abruptionFetal lossGrowth restrictionRisk factorsClinical conditionsLarge cohortNonbiased mannerBiomarker developmentThromboembolismPreeclampsiaComplicationsPregnancyRelevant diseases
2017
LB02: Randomized double-blind placebo controlled evaluation of the safety and efficacy of recombinant Antithrombin versus placebo in preterm preeclampsia
Sibai B, Paidas M, Group T. LB02: Randomized double-blind placebo controlled evaluation of the safety and efficacy of recombinant Antithrombin versus placebo in preterm preeclampsia. American Journal Of Obstetrics And Gynecology 2017, 216: s559-s560. DOI: 10.1016/j.ajog.2016.11.1048.Peer-Reviewed Original Research
2013
Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1)
Paidas MJ, Sibai BM, Triche EW, Frieling J, Lowry S, Group T. Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1). American Journal Of Reproductive Immunology 2013, 69: 539-544. PMID: 23444920, DOI: 10.1111/aji.12091.Peer-Reviewed Original ResearchConceptsProspective Randomized EvaluationAntithrombin replacementWeeks' gestationRandomized EvaluationRecombinant antithrombinTreatment of preeclampsiaRecombinant human ATExpectant managementPreterm preeclampsiaPrimary endpointMaternal indicationsGestational ageStudy enrollmentAT therapyPreeclampsia studyPreeclampsiaGestationHuman ATAT replacementPharmacokinetic activityAntithrombinEfficacySafetyLaboratory assaysDelivery
2012
Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort
LYKKE JA, BARE LA, OLSEN J, LAGIER R, ARELLANO AR, TONG C, PAIDAS MJ, LANGHOFF‐ROOS J. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. Journal Of Thrombosis And Haemostasis 2012, 10: 1320-1325. PMID: 22578003, DOI: 10.1111/j.1538-7836.2012.04773.x.Peer-Reviewed Original ResearchConceptsMethylenetetrahydrofolate reductase (MTHFR) C677TFetal growth restrictionProthrombin mutation G20210APlacental abruptionSevere preeclampsiaGrowth restrictionAllelic modelAdverse pregnancy outcomesBody mass indexCase-cohort studyReductase C677TPreterm deliveryComposite outcomePregnancy outcomesMass indexPregnant womenMedical recordsC677TFV LeidenStudy designSocioeconomic statusPreeclampsiaAbruptionRandom controlsOutcomes
2007
Do Thrombophilias Cause Placenta-Mediated Pregnancy Complications?
Rodger M, Paidas M. Do Thrombophilias Cause Placenta-Mediated Pregnancy Complications? Seminars In Thrombosis And Hemostasis 2007, 33: 597-603. PMID: 17768692, DOI: 10.1055/s-2007-985756.Peer-Reviewed Original ResearchConceptsPlacenta-mediated pregnancy complicationsPregnancy complicationsAnticoagulant prophylaxisIntrauterine growth restrictionThrombophilic pregnanciesNeonatal morbidityPlacental abruptionVenous thromboembolismThrombophilic womenPregnancy lossGrowth restrictionClinical consequencesHigh riskThrombophiliaComplicationsCausal associationProphylaxisAssociationThromboembolismAbruptionPreeclampsiaMorbidityEvidencePregnancyNew associations